-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK's Jideytro Achieves 94% Objective Response Rate At 15.2 Months Follow-Up In TKI-Naïve ROS1-Positive NSCLC, ARROS-1 Trial Shows

Benzinga·09/14/2026 08:24:33
Listen to the news
  • 94% objective response rate at 15.2 months follow-up
  • 90% of patients were progression free at 12 months, with median PFS rate still to be reached
  • 70% of patients with measurable brain metastases achieved complete clearance of detectable brain tumours
  • Results support potential to address key efficacy and tolerability needs in ROS1-positive NSCLC with US regulatory submission planned in 2026